Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MORPHOSYS AG

(MOR)
  Rapport
Geschatte realtime Tradegate  -  12:37:38 30-01-2023
18.00 EUR   -0.81%
25/01Biofarma, technologieaandelen leiden Europese aandelen iets lager
MT
24/01Farmaceutische aandelen drukken Europese aandelen in de dinsdaghandel
MT
19/01Farmaceutische aandelen drukken Europese aandelen in de donderdaghandel
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť MORPHOSYS AG
09/01Morphosys Ag : MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofib..
EQ
05/01MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financ..
EQ
05/01Ad Hoc : MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 20..
EQ
2022InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Tre..
AQ
2022Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
AQ
2022Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
EQ
2022MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Incl..
EQ
2022MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from F..
EQ
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
AQ
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
EQ
2022Afr : MorphoSys AG: Preliminary announcement of the publication of quarterly reports and q..
EQ
2022Morphosys Ag : Financial Calendar 2023
EQ
2022Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K
PU
2022Dd : MorphoSys AG: Krisja Vermeylen, buy
EQ
2022Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K
PU
2022Dd : MorphoSys AG: Dr. Marc Cluzel, buy
EQ
2022MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQ
2022MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
BU
2022MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gant..
AQ
2022MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gant..
EQ
2022Ad Hoc : MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program fo..
EQ
2022Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Cal..
AQ
2022Invitation to MorphoSys' Third Quarter and First Nine Months 2022 Results Conference Ca..
EQ
2022MorphoSys to Share New Data on Pelabresib and Monjuviģ (tafasitamab-cxix) in 14 Present..
EQ
2022MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat Supporting..
AQ
2022GSK, MorphoSys Licensing Partner, Provides Update on ContRAst Phase III Program for Oti..
AQ
2022MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)..
EQ
2022GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Ot..
EQ
2022MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance..
AQ
2022MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance..
EQ
2022Ad Hoc : MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial..
EQ
2022MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm..
AQ
2022MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm..
AQ
2022MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm..
EQ
2022InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab ..
AQ
2022MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following ..
AQ
2022MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following ..
EQ
2022Morphosys : Reports Second Quarter and First Half 2022 Financial Results - Form 6-K
PU
2022MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
EQ
2022MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
BU
2022Morphosys : Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Confe..
PU
2022Morphosys Ag : Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Co..
EQ
2022MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guida..
AQ
2022MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance..
AQ
2022Ad Hoc : MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial..
PU
2022MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance..
EQ
2022Ad Hoc : MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial..
EQ
2022Morphosys Group : First Quarter Interim Statement January – March 2022 - Form 6-K
PU
2022MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzarta..
EQ
2022MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzarta..
BU
2022Morphosys : Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monju..
PU
2022Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuviģ (tafa..
EQ
2022Morphosys : Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Pot..
PU
2022MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Po..
EQ
2022MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Po..
BU
2022MorphoSys AG Reports Outcome of Annual General Meeting 2022
AQ
2022MorphoSys AG Reports Outcome of Annual General Meeting 2022
EQ
2022MorphoSys to Present New Data on Pelabresib and Monjuviģ (tafasitamab-cxix) at the 2022..
EQ
2022MorphoSys to Present New Data on Pelabresib and Monjuviģ (tafasitamab-cxix) at the 2022..
BU
2022MorphoSys AG Reports First Quarter 2022 Financial Results
EQ
2022MorphoSys AG Reports First Quarter 2022 Financial Results
BU
2022Morphosys : Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call ..
PU
2022Morphosys : Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call ..
PU
2022Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5,..
EQ
2022Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K
PU
2022Morphosys Ag : Notification and public disclosure of transactions by persons
EQ
2022MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi (tafasitamab) in..
AQ
2022Morphosys : and Incyte Announce Swissmedic Temporary Approval of Minjuviģ (tafasitamab) in..
PU
2022MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab)..
EQ
2022Morphosys : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo..
PU
2022Morphosys : ESG Report 2021
PU
2022MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C..
BU
2022MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C..
EQ
2022Morphosys : National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (ta..
PU
2022Morphosys : National Comprehensive Cancer Networkģ Updates Designation of Monjuviģ (tafasi..
PU
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op MORPHOSYS AG